Lymphoedema can occur secondary to treatment for cancer. It is currently diagnosed using methods which do not allow for early diagnosis, allowing significant tissue damage to occur before treatment is commenced. The aim of this research proposal is to improve the detection and diagnosis of lymphoedema so that it can be treated as early as possible, preventing permanent tissue damage and potentially improving prognosis.
Characterisation Of The Molecular Pathogenesis Of Cancer Cachexia Syndrome In Colorectal Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$100,381.00
Summary
Cachexia is a hypermetabolic wasting syndrome involving depletion of both fat and muscle which affects 80% of cancer patients. The exact mechanisms of this syndrome are unknown at the molecular level and this affects our ability to predict, prevent or treat this problem. This study aims to elucidate the molecular mechanisms of cancer cachexia syndrome with a view to implementing nutritional, exercise and pharmacological interventions to prevent its onset.
Biomarkers Of Phenotype, Prognosis And Response To Therapy In Pancreatic Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$105,845.00
Summary
Pancreatic cancer (PC) is the 4th leading cause of cancer deaths in our society. This research is aimed at the discovery of novel biomarkers with the ability to forecast prognosis and response to treatments in patients with PC. Ultimately, this will lead to the “individualisation” of the treatment for each patient, so that the most appropriate therapy could be given to an individual patient. This would significantly improve the overall survival and the quality of life for patients.
Gene And Environmental Factors Influencing The Risk And Outcome Of Childhood Neuroblastoma.
Funder
National Health and Medical Research Council
Funding Amount
$91,573.00
Summary
Neuroblastoma is the most common solid tumour of early childhood. The proposed project will identify gene variations as well as birth characteristics and perinatal factors associated with the cause of neuroblastoma. Understanding the genetic causes of the disease can potentially identify genetic targets for treatment and improve diagnosis, while the identification of risk factors can be translated into interventions for prevention of neuroblastoma.